Skip to main content

Main menu

  • Home
  • Articles
    • Current
    • Special Feature Articles - Most Recent
    • Special Features
    • Colloquia
    • Collected Articles
    • PNAS Classics
    • List of Issues
  • Front Matter
    • Front Matter Portal
    • Journal Club
  • News
    • For the Press
    • This Week In PNAS
    • PNAS in the News
  • Podcasts
  • Authors
    • Information for Authors
    • Editorial and Journal Policies
    • Submission Procedures
    • Fees and Licenses
  • Submit
  • Submit
  • About
    • Editorial Board
    • PNAS Staff
    • FAQ
    • Accessibility Statement
    • Rights and Permissions
    • Site Map
  • Contact
  • Journal Club
  • Subscribe
    • Subscription Rates
    • Subscriptions FAQ
    • Open Access
    • Recommend PNAS to Your Librarian

User menu

  • Log in
  • My Cart

Search

  • Advanced search
Home
Home
  • Log in
  • My Cart

Advanced Search

  • Home
  • Articles
    • Current
    • Special Feature Articles - Most Recent
    • Special Features
    • Colloquia
    • Collected Articles
    • PNAS Classics
    • List of Issues
  • Front Matter
    • Front Matter Portal
    • Journal Club
  • News
    • For the Press
    • This Week In PNAS
    • PNAS in the News
  • Podcasts
  • Authors
    • Information for Authors
    • Editorial and Journal Policies
    • Submission Procedures
    • Fees and Licenses
  • Submit
Research Article

Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation

Shengkan Jin, Barbara Gorfajn, Glynn Faircloth, and Kathleen W. Scotto
  1. *Molecular Pharmacology and Therapeutics Program, Memorial Sloan–Kettering Cancer Center and the Weill Graduate School of Medical Sciences of Cornell University, 1275 York Avenue, New York, NY 10021; and †PharmaMar USA, 320 Putnam Avenue, Cambridge, MA 02139

See allHide authors and affiliations

PNAS June 6, 2000 97 (12) 6775-6779; https://doi.org/10.1073/pnas.97.12.6775
Shengkan Jin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Barbara Gorfajn
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Glynn Faircloth
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kathleen W. Scotto
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  1. Edited by Samuel J. Danishefsky, Memorial Sloan–Kettering Cancer Center, New York, NY, and approved April 3, 2000 (received for review November 29, 1999)

  • Article
  • Figures & SI
  • Info & Metrics
  • PDF
Loading

Online Impact

 

Article Information

vol. 97 no. 12 6775-6779
DOI: 
https://doi.org/10.1073/pnas.97.12.6775
PubMed: 
10841572

Published By: 
National Academy of Sciences
Print ISSN: 
0027-8424
Online ISSN: 
1091-6490
History: 
  • Received November 29, 1999
  • Published June 6, 2000.

Copyright & Usage: 
Copyright © 2000, The National Academy of Sciences

Author Information

  1. Shengkan Jin*,
  2. Barbara Gorfajn*,
  3. Glynn Faircloth†, and
  4. Kathleen W. Scotto*‡
  1. *Molecular Pharmacology and Therapeutics Program, Memorial Sloan–Kettering Cancer Center and the Weill Graduate School of Medical Sciences of Cornell University, 1275 York Avenue, New York, NY 10021; and †PharmaMar USA, 320 Putnam Avenue, Cambridge, MA 02139
  1. Edited by Samuel J. Danishefsky, Memorial Sloan–Kettering Cancer Center, New York, NY, and approved April 3, 2000 (received for review November 29, 1999)

Footnotes

    • ↵‡ To whom reprint requests should be addressed. E-mail: k-scotto{at}ski.mskcc.org.

    • This paper was submitted directly (Track II) to the PNAS office.

    Cited By...

    • 186 Citations
    • 140 Citations
    • Google Scholar

    This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

    • DNA and its associated processes as targets for cancer therapy
      Laurence H. Hurley
      Nature Reviews Cancer 2002 2 3
    • Chemistry and Biology of the Tetrahydroisoquinoline Antitumor Antibiotics
      Jack D. Scott, Robert M. Williams
      Chemical Reviews 2002 102 5
    • The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux
      Timothy W. Synold, Isabelle Dussault, Barry Marc Forman
      Nature Medicine 2001 7 5
    • Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention
      F Chang, L S Steelman, J T Lee, J G Shelton, P M Navolanic, W L Blalock, R A Franklin, J A McCubrey
      Leukemia 2003 17 7
    • A Review of Trabectedin (ET-743): A Unique Mechanism of Action
      Maurizio D'Incalci, Carlos M. Galmarini
      Molecular Cancer Therapeutics 2010 9 8
    • Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair
      Yuji Takebayashi, Philippe Pourquier, Drazen B. Zimonjic, Kentaro Nakayama, Steffen Emmert, Takahiro Ueda, Yoshimasa Urasaki, Atsuko Kanzaki, Shin-ichi Akiyama, Nicholas Popescu, Kenneth H. Kraemer, Yves Pommier
      Nature Medicine 2001 7 8
    • Phase II and Pharmacokinetic Study of Ecteinascidin 743 in Patients With Progressive Sarcomas of Soft Tissues Refractory to Chemotherapy
      R. Garcia-Carbonero, J.G. Supko, J. Manola, M.V. Seiden, D. Harmon, D.P. Ryan, M.T. Quigley, P. Merriam, J. Canniff, G. Goss, U. Matulonis, R.G. Maki, T. Lopez, T.A. Puchalski, M.A. Sancho, J. Gomez, C. Guzman, J. Jimeno, G.D. Demetri
      Journal of Clinical Oncology 2004 22 8
    • Anti-inflammatory Properties of the Novel Antitumor Agent Yondelis (Trabectedin): Inhibition of Macrophage Differentiation and Cytokine Production
      Paola Allavena, Mauro Signorelli, Marcello Chieppa, Eugenio Erba, Giancarlo Bianchi, Federica Marchesi, Chiara Omero Olimpio, Claudia Bonardi, Annalisa Garbi, Andrea Lissoni, Filippo de Braud, José Jimeno, Maurizio D'Incalci
      Cancer Research 2005 65 7
    • Synthesis of Ecteinascidin ET-743 and Phthalascidin Pt-650 from Cyanosafracin B
      Carmen Cuevas, Marta Pérez, María J. Martín, Jose L. Chicharro, Carolina Fernández-Rivas, María Flores, Andrés Francesch, Pilar Gallego, María Zarzuelo, Fernando de la Calle, Jesús García, Concepción Polanco, Ignacio Rodríguez, Ignacio Manzanares
      Organic Letters 2000 2 16
    • Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action
      E Erba, D Bergamaschi, L Bassano, G Damia, S Ronzoni, G.T Faircloth, M D'Incalci
      European Journal of Cancer 2001 37 1
    • Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743
      M. Minuzzo, S. Marchini, M. Broggini, G. Faircloth, M. D'Incalci, R. Mantovani
      Proceedings of the National Academy of Sciences 2000 97 12
    • NF-Y and the transcriptional activation of CCAAT promoters
      Diletta Dolfini, Raffaella Gatta, Roberto Mantovani
      Critical Reviews in Biochemistry and Molecular Biology 2012 47 1
    • Ecteinascidin-743 (ET-743) for Chemotherapy-Naive Patients With Advanced Soft Tissue Sarcomas: Multicenter Phase II and Pharmacokinetic Study
      R. Garcia-Carbonero, J.G. Supko, R.G. Maki, J. Manola, D.P. Ryan, D. Harmon, T.A. Puchalski, G. Goss, M.V. Seiden, A. Waxman, M.T. Quigley, T. Lopez, M.A. Sancho, J. Jimeno, C. Guzman, G.D. Demetri
      Journal of Clinical Oncology 2005 23 24
    • Trabectedin for Women With Ovarian Carcinoma After Treatment With Platinum and Taxanes Fails
      Cristiana Sessa, Filippo De Braud, Antonella Perotti, Jean Bauer, Giuseppe Curigliano, Cristina Noberasco, Flavia Zanaboni, Luca Gianni, Silvia Marsoni, José Jimeno, Maurizio D'Incalci, Elisa Dall’ó, Nicoletta Colombo
      Journal of Clinical Oncology 2005 23 9
    • Ecteinascidin-743: A Marine-Derived Compound in Advanced, Pretreated Sarcoma Patients—Preliminary Evidence of Activity
      S. Delaloge, A. Yovine, A. Taamma, M. Riofrio, E. Brain, E. Raymond, P. Cottu, F. Goldwasser, J. Jimeno, J. L. Misset, M. Marty, E. Cvitkovic
      Journal of Clinical Oncology 2001 19 5
    • Phase I and Pharmacokinetic Study of Ecteinascidin-743, a New Marine Compound, Administered as a 24-hour Continuous Infusion in Patients With Solid Tumors
      A. Taamma, J. L. Misset, M. Riofrio, C. Guzman, E. Brain, L. Lopez Lazaro, H. Rosing, J. M. Jimeno, E. Cvitkovic
      Journal of Clinical Oncology 2001 19 5
    • Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors
      Claudia Forni, Mario Minuzzo, Emanuela Virdis, Elena Tamborini, Matteo Simone, Michele Tavecchio, Eugenio Erba, Federica Grosso, Alessandro Gronchi, Pierre Aman, Paolo Casali, Maurizio D'Incalci, Silvana Pilotti, Roberto Mantovani
      Molecular Cancer Therapeutics 2009 8 2
    • Marine pharmacology in 2000: Antitumor and cytotoxic compounds
      Alejandro M.S. Mayer, Kirk R. Gustafson
      International Journal of Cancer 2003 105 3
    • New Marine Derived Anticancer Therapeutics ─ A Journey from the Sea to Clinical Trials
      J. Jimeno, G. Faircloth, JM Sousa-Faro, P. Scheuer, K. Rinehart
      Marine Drugs 2004 2 1
    • Ecteinascidin 743: a novel anticancer drug with a unique mechanism of action
      Gregory J Aune, Takahisa Furuta, Yves Pommier
      Anti-Cancer Drugs 2002 13 6
    • Trabectedin, a drug acting on both cancer cells and the tumour microenvironment
      M D’Incalci, N Badri, C M Galmarini, P Allavena
      British Journal of Cancer 2014 111 4
    • P-glycoprotein (MDR1) Expression in Leukemic Cells Is Regulated at Two Distinct Steps, mRNA Stabilization and Translational Initiation
      Ernesto Yagüe, Angel L. Armesilla, Georgina Harrison, James Elliott, Alessandro Sardini, Christopher F. Higgins, Selina Raguz
      Journal of Biological Chemistry 2003 278 12
    • Targeting Transcription Factors for Cancer Treatment
      Mélanie Lambert, Samy Jambon, Sabine Depauw, Marie-Hélène David-Cordonnier
      Molecules 2018 23 6
    • Multidrug Resistance/P-Glycoprotein and Breast Cancer: Review and Meta-Analysis
      Robert Clarke, Fabio Leonessa, Bruce Trock
      Seminars in Oncology 2005 32
    • Ecteinascidins. A review of the chemistry, biology and clinical utility of potent tetrahydroisoquinoline antitumor antibiotics
      V. H. Le, M. Inai, R. M. Williams, T. Kan
      Natural Product Reports 2015 32 2
    • A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas
      Axel Le Cesne, Sara Cresta, Robert G. Maki, Jean Yves Blay, Jaap Verweij, Andrés Poveda, Paolo G. Casali, Carme Balaña, Patrick Schöffski, Federica Grosso, Pilar Lardelli, Antonio Nieto, Vicente Alfaro, George D. Demetri
      European Journal of Cancer 2012 48 16
    • Unique features of trabectedin mechanism of action
      Annette K. Larsen, Carlos M. Galmarini, Maurizio D’Incalci
      Cancer Chemotherapy and Pharmacology 2016 77 4
    • The effects of cannabinoids on P-glycoprotein transport and expression in multidrug resistant cells
      M.L. Holland, J.A. Panetta, J.M. Hoskins, M. Bebawy, B.D. Roufogalis, J.D. Allen, J.C. Arnold
      Biochemical Pharmacology 2006 71 8
    • Natural alkaloids as P-gp inhibitors for multidrug resistance reversal in cancer
      Prashant Joshi, Ram A. Vishwakarma, Sandip B. Bharate
      European Journal of Medicinal Chemistry 2017 138
    • Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma
      Caroline Laverdiere, E. Anders Kolb, Jeffrey G. Supko, Richard Gorlick, Paul A. Meyers, Robert G. Maki, Leonard Wexler, George D. Demetri, John H. Healey, Andrew G. Huvos, Allen M. Goorin, Rochelle Bagatell, Ana Ruiz-Casado, Cecilia Guzman, Jose Jimeno, David Harmon
      Cancer 2003 98 4
    • DNA minor groove binders: Back in the groove
      Xuemei Cai, Phillip J. Gray, Daniel D. Von Hoff
      Cancer Treatment Reviews 2009 35 5
    • Antitumor activity- and gene expression-based profiling of ecteinascidin Et 743 and phthalascidin Pt 650
      Eduardo J Martinez, E.J Corey, Takashi Owa
      Chemistry & Biology 2001 8 12
    • Mode of action of trabectedin in myxoid liposarcomas
      S Di Giandomenico, R Frapolli, E Bello, S Uboldi, S A Licandro, S Marchini, L Beltrame, S Brich, V Mauro, E Tamborini, S Pilotti, P G Casali, F Grosso, R Sanfilippo, A Gronchi, R Mantovani, R Gatta, C M Galmarini, J M F Sousa-Faro, M D'Incalci
      Oncogene 2014 33 44
    • Up-regulation of MDR1 and induction of doxorubicin resistance by histone deacetylase inhibitor depsipeptide (FK228) and ATRA in acute promyelocytic leukemia cells
      Yoko Tabe, Marina Konopleva, Rooha Contractor, Mark Munsell, Wendy D. Schober, Linhua Jin, Yuko Tsutsumi-Ishii, Isao Nagaoka, Jun Igari, Michael Andreeff
      Blood 2006 107 4
    • Phase I and pharmacokinetic study of Yondelis™ (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours
      C. Twelves, K. Hoekman, A. Bowman, J.B. Vermorken, A. Anthoney, J. Smyth, C. van Kesteren, J.H. Beijnen, J. Uiters, J. Wanders, J. Gomez, C. Guzmán, J. Jimeno, A. Hanauske
      European Journal of Cancer 2003 39 13
    • From old alkylating agents to new minor groove binders
      Stéphane Puyo, Danièle Montaudon, Philippe Pourquier
      Critical Reviews in Oncology/Hematology 2014 89 1
    • The inefficiency of incisions of ecteinascidin 743–DNA adducts by the UvrABC nuclease and the unique structural feature of the DNA adducts can be used to explain the repair-dependent toxicities of this antitumor agent
      Maha Zewail-Foote, Ven-Shun Li, Harold Kohn, David Bearss, Mary Guzman, Laurence H Hurley
      Chemistry & Biology 2001 8 11
    • Complete reversal of multidrug resistance by stable expression of small interfering RNAs targeting MDR1
      E Yagüe, C F Higgins, S Raguz
      Gene Therapy 2004 11 14
    • Yondelis® (trabectedin, ET-743): the development of an anticancer agent of marine origin
      Ch. van Kesteren, M. M. M. de Vooght, L. López-Lázaro, R. A. A. Mathôt, J. H. M. Schellens, J. M. Jimeno, J. H. Beijnen
      Anti-Cancer Drugs 2003 14 7
    • Cancer wars: natural products strike back
      Christine Basmadjian, Qian Zhao, Embarek Bentouhami, Amel Djehal, Canan G. Nebigil, Roger A. Johnson, Maria Serova, Armand de Gramont, Sandrine Faivre, Eric Raymond, Laurent G. Désaubry
      Frontiers in Chemistry 2014 2
    • Differential Cytostatic and Apoptotic Effects of Ecteinascidin-743 in Cancer Cells
      Consuelo Gajate, Feiyun An, Faustino Mollinedo
      Journal of Biological Chemistry 2002 277 44
    • Preclinical and clinical results with the natural marine product ET-743
      Maurizio D’Incalci, José Jimeno
      Expert Opinion on Investigational Drugs 2003 12 11
    • Multi-Drug Resistance in Cancer
      Chow H. Lee
      2010 596
    • Pregnane X receptor and natural products: beyond drug–drug interactions
      Jeff L Staudinger, Xunshan Ding, Kristin Lichti
      Expert Opinion on Drug Metabolism & Toxicology 2006 2 6
    • Pharmaceutical development of anticancer agents derived from marine sources
      B Nuijen, M Bouma, C Manada, J M Jimeno, J HM Schellens, A Bult, J H Beijnen
      Anti-Cancer Drugs 2000 11 10
    • Transcriptional signature of Ecteinascidin 743 (Yondelis, Trabectedin) in human sarcoma cells explanted from chemo-naïve patients
      Nerea Martínez, Margarita Sánchez-Beato, Amancio Carnero, Victoria Moneo, Juan C. Tercero, Isabel Fernández, Mercedes Navarrete, José Jimeno, Miguel A. Piris
      Molecular Cancer Therapeutics 2005 4 5
    • ET-743: a novel agent with activity in soft-tissue sarcomas
      Jérôme Fayette, Isabelle Ray Coquard, Laurent Alberti, Helen Boyle, Pierre Méeus, Anne-Valérie Decouvelaere, Philippe Thiesse, Marie-Pierre Sunyach, Dominique Ranchère, Jean-Yves Blay
      Current Opinion in Oncology 2006 18 4
    • Synthetic Studies on Ecteinascidin-743:  Constructing a Versatile Pentacyclic Intermediate for the Synthesis of Ecteinascidins and Saframycins
      Wei Jin, Sammy Metobo, Robert M. Williams
      Organic Letters 2003 5 12
    • Clinical impact of trabectedin (ecteinascidin-743) in advanced/metastatic soft tissue sarcoma
      Patrick Schöffski, Herlinde Dumez, Pascal Wolter, Cristiana Stefan, Agnieszka Wozniak, Jose Jimeno, Allan T Van Oosterom
      Expert Opinion on Pharmacotherapy 2008 9 9
    • Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer
      C. Sessa, A. Perotti, C. Noberasco, F. De Braud, E. Gallerani, S. Cresta, M. Zucchetti, L. Viganò, A. Locatelli, J. Jimeno, J.W. Feilchenfeldt, M. D’Incalci, G. Capri, N. Ielmini, L. Gianni
      European Journal of Cancer 2009 45 7
    • A Phase II and Pharmacokinetic Study of Ecteinascidin 743 in Patients with Gastrointestinal Stromal Tumors
      David P. Ryan, Thomas Puchalski, Jeffrey G. Supko, David Harmon, Robert Maki, Rocio Garcia‐Carbonero, Caroline Kuhlman, Jennifer Winkelman, Priscilla Merriam, Travis Quigley, Jose Jimeno, Judith Manola, George D. Demetri
      The Oncologist 2002 7 6
    • Clinical pharmacology of the novel marine-derived anticancer agent Ecteinascidin 743 administered as a 1- and 3-h infusion in a phase I study
      Charlotte van Kesteren, Chris Twelves, Angela Bowman, Klaas Hoekman, Luis López-Lázaro, José Jimeno, Cecilia Guzman, Ron AA Mathôt, Andrew Simpson, Jan B Vermorken, John Smyth, Jan HM Schellens, Michel JX Hillebrand, Hilde Rosing, Jos H Beijnen
      Anti-Cancer Drugs 2002 13 4
    • Unique Features of the Mode of Action of ET‐743
      Maurizio D'Incalci, Eugenio Erba, Giovanna Damia, Emanuela Galliera, Laura Carrassa, Sergio Marchini, Roberto Mantovani, Gianluca Tognon, Robert Fruscio, José Jimeno, Glynn T. Faircloth
      The Oncologist 2002 7 3
    • Influence of combinations of digitonin with selected phenolics, terpenoids, and alkaloids on the expression and activity of P-glycoprotein in leukaemia and colon cancer cells
      Safaa Yehia Eid, Mahmoud Zaki El-Readi, Essam Eldin Mohamed Nour Eldin, Sameer Hassan Fatani, Michael Wink
      Phytomedicine 2013 21 1
    • Evaluation of Biosynthetic Pathway and Engineered Biosynthesis of Alkaloids
      Shinji Kishimoto, Michio Sato, Yuta Tsunematsu, Kenji Watanabe
      Molecules 2016 21 8
    • Selective Effects of the Anticancer Drug Yondelis (ET-743) on Cell-Cycle Promoters
      Mario Minuzzo, Michele Ceribelli, Marià Pitarque-Martì, Serena Borrelli, Eugenio Erba, Alberto diSilvio, Maurizio D'Incalci, Roberto Mantovani
      Molecular Pharmacology 2005 68 5
    • ET‐743: A Novel Agent with Activity in Soft Tissue Sarcomas
      Jérôme Fayette, Isabelle Ray Coquard, Laurent Alberti, Dominique Ranchère, Helen Boyle, Jean‐Yves Blay
      The Oncologist 2005 10 10
    • Von Hippel-Lindau–Coupled and Transcription-Coupled Nucleotide Excision Repair–Dependent Degradation of RNA Polymerase II in Response to Trabectedin
      Gregory J. Aune, Kazutaka Takagi, Olivier Sordet, Josée Guirouilh-Barbat, Smitha Antony, Vilhelm A. Bohr, Yves Pommier
      Clinical Cancer Research 2008 14 20
    • Extreme sensitivity to Yondelis® (Trabectedin, ET-743) in low passaged sarcoma cell lines correlates with mutated p53
      Victoria Moneo, Beatriz G. Serelde, Jesús Fominaya, Juan F.M. Leal, Carmen Blanco-Aparicio, Lourdes Romero, Margarita Sánchez-Beato, Juan C. Cigudosa, Juan C. Tercero, Miguel A. Piris, Jose Jimeno, Amancio Carnero
      Journal of Cellular Biochemistry 2007 100 2
    • Hepatotoxicity and metabolism of trabectedin: a literature review
      J.H. Beumer, J.H.M. Schellens, J.H. Beijnen
      Pharmacological Research 2005 51 5
    • Increased sensitivity to platinum drugs of cancer cells with acquired resistance to trabectedin
      B Colmegna, S Uboldi, R Frapolli, S A Licandro, N Panini, C M Galmarini, Nadia Badri, V J Spanswick, J P Bingham, Konstantinos Kiakos, E Erba, J A Hartley, M D'Incalci
      British Journal of Cancer 2015 113 12
    • NF-Y in cancer: Impact on cell transformation of a gene essential for proliferation
      Aymone Gurtner, Isabella Manni, Giulia Piaggio
      Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms 2017 1860 5
    • Synthesis and Cytotoxic Evaluation of Some Cribrostatin–Ecteinascidin Analogues
      Benjamin J. D. Wright, Collin Chan, Samuel J. Danishefsky
      Journal of Natural Products 2008 71 3
    • Trabectedin (YondelisTM, formerly ET-743), a mass balance study in patients with advanced cancer
      J. H. Beumer, J. M. Rademaker-Lakhai, H. Rosing, L. Lopez-Lazaro, J. H. Beijnen, J. H. M. Schellens
      Investigational New Drugs 2005 23 5
    • XPF-Dependent DNA Breaks and RNA Polymerase II Arrest Induced by Antitumor DNA Interstrand Crosslinking-Mimetic Alkaloids
      Sascha Feuerhahn, Christophe Giraudon, Marta Martínez-Díez, Juan A. Bueren-Calabuig, Carlos M. Galmarini, Federico Gago, Jean-Marc Egly
      Chemistry & Biology 2011 18 8
    • Transcriptional Response Pathways in a Yeast Strain Sensitive to Saframycin A and a More Potent Analog
      Alleyn T. Plowright, Scott E. Schaus, Andrew G. Myers
      Chemistry & Biology 2002 9 5
    • Ecteinascidin-743 drug resistance in sarcoma cells: transcriptional and cellular alterations
      Li Shao, Jeremy Kasanov, Francis J. Hornicek, Takeshi Morii, Gertrude Fondren, Lawrence Weissbach
      Biochemical Pharmacology 2003 66 12
    • Assessment by Molecular Dynamics Simulations of the Structural Determinants of DNA-binding Specificity for Transcription Factor Sp1
      Esther Marco, Raquel Garcı́a-Nieto, Federico Gago
      Journal of Molecular Biology 2003 328 1
    • Histone deacetylase inhibitors and transforming growth factor-β induce 15-hydroxyprostaglandin dehydrogenase expression in human lung adenocarcinoma cells
      Min Tong, Yunfei Ding, Hsin-Hsiung Tai
      Biochemical Pharmacology 2006 72 6
    • In vitro toxicity of ET-743 and aplidine, two marine-derived antineoplastics, on human bone marrow haematopoietic progenitors
      B Albella, G Faircloth, L López-Lázaro, C Guzmán, J Jimeno, J.A Bueren
      European Journal of Cancer 2002 38 10
    • Marine Natural Products as Models to Circumvent Multidrug Resistance
      Solida Long, Emília Sousa, Anake Kijjoa, Madalena Pinto
      Molecules 2016 21 7
    • New therapies in soft tissue sarcoma
      Bruno Vincenzi, Anna Maria Frezza, Daniele Santini, Giuseppe Tonini
      Expert Opinion on Emerging Drugs 2010 15 2
    • Novel Models of Myxoid Liposarcoma Xenografts Mimicking the Biological and Pharmacologic Features of Human Tumors
      Roberta Frapolli, Elena Tamborini, Emanuela Virdis, Ezia Bello, Eva Tarantino, Sergio Marchini, Federica Grosso, Roberta Sanfilippo, Alessandro Gronchi, Juan Carlos Tercero, Gabriella Peloso, Paolo Casali, Silvana Pilotti, Maurizio D'Incalci
      Clinical Cancer Research 2010 16 20
    • Synthetic studies on ecteinascidin 743: asymmetric synthesis of the versatile amino acid component
      Wei Jin, Robert M Williams
      Tetrahedron Letters 2003 44 25
    • Biological Reactive Intermediates VI
      Laurence H. Hurley, Maha Zewail-Foote
      2001 500
    • Optimal management of uterine leiomyosarcoma
      Roisin O’Cearbhaill, Martee L Hensley
      Expert Review of Anticancer Therapy 2010 10 2
    • Telomere Dysfunction Increases Cisplatin and Ecteinascidin-743 Sensitivity of Melanoma Cells
      Annamaria Biroccio, Chiara Gabellini, Sarah Amodei, Barbara Benassi, Donatella Del Bufalo, Raffaella Elli, Anna Antonelli, Maurizio D'Incalci, Gabriella Zupi
      Molecular Pharmacology 2003 63 3
    • Enriching cancer pharmacology with drugs of marine origin
      Paula C. Jimenez, Diego V. Wilke, Paola C. Branco, Anelize Bauermeister, Paula Rezende‐Teixeira, Susana P. Gaudêncio, Leticia V. Costa‐Lotufo
      British Journal of Pharmacology 2020 177 1
    • Metabolism of trabectedin (ET-743, Yondelis™) in patients with advanced cancer
      Jan H. Beumer, Jeany M. Rademaker-Lakhai, Hilde Rosing, Michel J. X. Hillebrand, Tessa M. Bosch, Luis Lopez-Lazaro, Jan H. M. Schellens, Jos H. Beijnen
      Cancer Chemotherapy and Pharmacology 2007 59 6
    • Mode of action of microbial bioactive metabolites
      V. Běhal
      Folia Microbiologica 2006 51 5
    • Characterization of a new trabectedin-resistant myxoid liposarcoma cell line that shows collateral sensitivity to methylating agents
      S. Uboldi, S. Bernasconi, M. Romano, S. Marchini, I. Fuso Nerini, G. Damia, M. Ganzinelli, E. Marangon, F. Sala, L. Clivio, G. Chiorino, S. Di Giandomenico, M. Rocchi, O. Capozzi, G.P. Margison, A.J. Watson, A.M. Caccuri, A. Pastore, A. Fossati, R. Mantovani, F. Grosso, J.C. Tercero, E. Erba, M. D'Incalci
      International Journal of Cancer 2012 131 1
    • The impairment of the High Mobility Group A (HMGA) protein function contributes to the anticancer activity of trabectedin
      Daniela D’Angelo, Eleonora Borbone, Dario Palmieri, Sarah Uboldi, Francesco Esposito, Roberta Frapolli, Roberto Pacelli, Maurizio D’Incalci, Alfredo Fusco
      European Journal of Cancer 2013 49 5
    • Ascidian Toxins with Potential for Drug Development
      Dianne Watters
      Marine Drugs 2018 16 5
    • Combination of trabectedin and irinotecan is highly effective in a human rhabdomyosarcoma xenograft
      Anna Riccardi, Daniela Meco, Paolo Ubezio, Giorgio Mazzarella, Mirko Marabese, Glynn T Faircloth, José Jimeno, Maurizio D'Incalci, Riccardo Riccardi
      Anti-Cancer Drugs 2005 16 8
    • Molecular characterisation of two human cancer cell lines selected in vitro for their chemotherapeutic drug resistance to ET-743
      S. Marchini, E. Marrazzo, R. Bonomi, G. Chiorino, M. Zaffaroni, L. Weissbach, F.J. Hornicek, M. Broggini, G.T. Faircloth, M. D’Incalci
      European Journal of Cancer 2005 41 2
    • Synthesis and inhibition of cancer cell proliferation of (1,3′)-bis-tetrahydroisoquinolines and piperazine systems
      Sylvain Aubry, Stéphane Pellet-Rostaing, Jérémie Fournier dit Chabert, Sylvie Ducki, Marc Lemaire
      Bioorganic & Medicinal Chemistry Letters 2007 17 9
    • Trabectedin for the treatment of breast cancer
      Maurizio D’Incalci, Alberto Zambelli
      Expert Opinion on Investigational Drugs 2016 25 1
    • Phase I and Pharmacokinetic Study of Sequential Paclitaxel and Trabectedin Every 2 Weeks in Patients with Advanced Solid Tumors
      Quincy Chu, Alain Mita, Bahram Forouzesh, Anthony W. Tolcher, Gary Schwartz, Antonio Nieto, Arturo Soto-Matos, Vicente Alfaro, Claudia Lebedinsky, Eric K. Rowinsky
      Clinical Cancer Research 2010 16 9
    • Wide-spectrum characterization of trabectedin: biology, clinical activity and future perspectives
      Bruno Vincenzi, Andrea Napolitano, Anna Maria Frezza, Gaia Schiavon, Daniele Santini, Giuseppe Tonini
      Pharmacogenomics 2010 11 6
    • A novel approach to the synthesis of diaza-bridged heterocycle derivatives
      Isabel M. Gomez-Monterrey, Pietro Campiglia, Alessia Bertamino, Orazio Mazzoni, Maria V. Diurno, Ettore Novellino, Paolo Grieco
      Tetrahedron 2006 62 34
    • Reversing multidrug resistance by RNA interference through the suppression of MDR1 gene in human hepatoma cells
      Xiao-Ping Chen
      World Journal of Gastroenterology 2006 12 21
    • Ecteinascidin-743: Evidence of Activity in Advanced, Pretreated Soft Tissue and Bone Sarcoma Patients
      G. Huygh, Paul M. J. Clement, H. Dumez, P. Schöffski, H. Wildiers, J. Selleslach, J. M. Jimeno, I. De Wever, R. Sciot, L. Duck, A. T. Van Oosterom
      Sarcoma 2006 2006
    • In vitro radiosensitisation by trabectedin in human cancer cell lines
      Jesús Romero, Irma Zapata, Sofía Córdoba, José María Jimeno, José Antonio López-Martín, Juan Carlos Tercero, Alejandro De La Torre, Juan Antonio Vargas, Rafael Molerón, Ricardo Sánchez-Prieto
      European Journal of Cancer 2008 44 12
    • Trabectedin (ET-743, Yondelis™) is a substrate for P-glycoprotein, but only high expression of P-glycoprotein confers the multidrug resistance phenotype
      Jan-Hendrik Beumer, Tessa Buckle, Mariet Ouwehand, Niels E. F. Franke, Luis Lopez-Lazaro, Jan H. M. Schellens, Jos H. Beijnen, Olaf van Tellingen
      Investigational New Drugs 2007 25 1
    • Higher antitumor activity of trabectedin in germline BRCA2 carriers with advanced breast cancer as compared to BRCA1 carriers: A subset analysis of a dedicated phase II trial
      Amal Ghouadni, Suzette Delaloge, Pilar Lardelli, Carmen Kahatt, Tomasz Byrski, Joanne L. Blum, Anthony Gonçalves, Mario Campone, Antonio Nieto, Vicente Alfaro, Martin Cullell-Young, Jan Lubinski
      The Breast 2017 34
    • Protein Recognition in Drug-Induced DNA Alkylation: When the Moonlight Protein GAPDH Meets S23906-1/DNA Minor Groove Adducts
      Gaëlle Savreux-Lenglet, Sabine Depauw, Marie-Hélène David-Cordonnier
      International Journal of Molecular Sciences 2015 16 11
    • Protein recognition of the S23906-1–DNA adduct by nuclear proteins: direct involvement of glyceraldehyde-3-phosphate dehydrogenase (GAPDH)1
      Gaëlle Lenglet, Sabine Depauw, Denise Mendy, Marie-Hélène David-Cordonnier
      Biochemical Journal 2013 452 1
    • Targeting the EWS–FLI1 transcription factor in Ewing sarcoma
      R. Tancredi, A. Zambelli, G. A. DaPrada, V. Fregoni, L. Pavesi, A. Riccardi, S. Burdach, P. J. Grohar, M. D’Incalci
      Cancer Chemotherapy and Pharmacology 2015 75 6
    • Transcriptional Inhibition of Type I Collagen Gene Expression in Scleroderma Fibroblasts by the Antineoplastic Drug Ecteinascidin 743
      Natalia Louneva, Biagio Saitta, David J. Herrick, Sergio A. Jimenez
      Journal of Biological Chemistry 2003 278 41
    • Indirubin derivatives alter DNA binding activity of the transcription factor NF-Y and inhibit MDR1 gene promoter
      Toru Tanaka, Sachiyo Ohashi, Hiroaki Saito, Takashi Higuchi, Keiichi Tabata, Yasuhiro Kosuge, Takashi Suzuki, Shinichi Miyairi, Shunsuke Kobayashi
      European Journal of Pharmacology 2014 741
    • Effect of the novel antipsychotic drug perospirone on P-glycoprotein function and expression in Caco-2 cells
      Yan-Gang Zhou, Kun-Yan Li, Huan-De Li
      European Journal of Clinical Pharmacology 2008 64 7
    • Emergence of Multidrug Resistance in Leukemia Cells During Chemotherapy: Mechanisms and Prevention
      Alexander A. Shtil
      Journal of Hematotherapy & Stem Cell Research 2002 11 2
    • Resistance to minor groove binders
      Benedetta Colmegna, Sarah Uboldi, Eugenio Erba, Maurizio D’Incalci
      Drug Discovery Today: Technologies 2014 11
    • Asymmetric synthesis and cytotoxicity of (−)-saframycin A analogues
      Wenfang Dong, Wei Liu, Zheng Yan, Xiangwei Liao, Baohe Guan, Nan Wang, Zhanzhu Liu
      European Journal of Medicinal Chemistry 2012 49
    • Reversal of ABC Transporter-Dependent Multidrug Resistance in Cancer
      Ulrike Stein, Wolfgang Walther
      American Journal of Cancer 2006 5 5
    • Use of CFU-GM assay for prediction of human maximum tolerated dose of a new antitumoral drug: Yondelis™ (ET-743)
      Susana G. Gómez, Juan A. Bueren, Glynn Faircloth, Beatriz Albella
      Toxicology in Vitro 2003 17 5-6
    • Cytotoxicity mechanisms of pyrazino[1,2-b]isoquinoline-4-ones and SAR studies
      Irene Ortín, Juan Francisco González, Elena de la Cuesta, Cristina Manguan-García, Rosario Perona, Carmen Avendaño
      Bioorganic & Medicinal Chemistry 2009 17 23
    • Trabectedin
      Meredith K. Chuk, Frank M. Balis, Elizabeth Fox
      The Oncologist 2009 14 8
    • Disposition and toxicity of trabectedin (ET-743) in wild-type and mdr1 gene (P-gp) knock-out mice
      J. H. Beumer, N. E. Franke, R. Tolboom, T. Buckle, H. Rosing, L. Lopez-Lazaro, J. H. M. Schellens, J. H. Beijnen, O. van Tellingen
      Investigational New Drugs 2010 28 2
    • Escape from stress granule sequestration: another way to drug resistance?
      Ernesto Yagüe, Selina Raguz
      Biochemical Society Transactions 2010 38 6
    • Inhibitory effects of marine-derived DNA-binding anti-tumour tetrahydroisoquinolines on the Fanconi anaemia pathway
      Sandra Martínez, Laura Pérez, Carlos M Galmarini, Miguel Aracil, Juan C Tercero, Federico Gago, Beatriz Albella, Juan A Bueren
      British Journal of Pharmacology 2013 170 4
    • New drugs for the treatment of metastatic or refractory soft tissue sarcomas in children
      Abha A Gupta, Alberto S Pappo
      Future Oncology 2006 2 5
    • Therapeutic impact of ET-743 (Yondelis; trabectidin), a new marine-derived compound, in sarcoma
      Jose Jimeno, Robert G. Maki, Paolo Casali, Glynn Faircloth, Nerea Martinez, Antonio Nieto, Salvador Cañigueral, Kenneth Rinehart
      Current Opinion in Orthopaedics 2003 14 6
    • Targeting Molecular Mechanisms Underlying Treatment Efficacy and Resistance in Osteosarcoma: A Review of Current and Future Strategies
      Ingrid Lilienthal, Nikolas Herold
      International Journal of Molecular Sciences 2020 21 18
    • U7 snRNA acts as a transcriptional regulator interacting with an inverted CCAAT sequence-binding transcription factor NF-Y
      Takashi Higuchi, Kaijiro Anzai, Shunsuke Kobayashi
      Biochimica et Biophysica Acta (BBA) - General Subjects 2008 1780 2
    • Cytotoxicity of new pyrazino[1,2-b]isoquinoline and 6,15-iminoisoquino[3,2-b]3-benzazocine compounds
      Irene Ortín, Juan Francisco González, Elena de la Cuesta, Carmen Avendaño
      Bioorganic & Medicinal Chemistry 2010 18 18
    • DNA: Still A Target Worth Aiming At?
      D. Alan Anthoney, Chris J. Twelves
      American Journal of PharmacoGenomics 2001 1 1
    • Gene and microRNA modulation upon trabectedin treatment in a human intrahepatic cholangiocarcinoma paired patient derived xenograft and cell line
      Caterina Peraldo Neia, Giuliana Cavalloni, Giovanna Chiorino, Paola Ostano, Massimo Aglietta, Francesco Leone
      Oncotarget 2016 7 52
    • Yago Nieto
      2005 22
    • Marine Biotechnology II
      Gerd Liebezeit
      2005 97
    • Educational paper
      Terzah M. Horton, Stacey L. Berg
      European Journal of Pediatrics 2011 170 5
    • Sarcoma
      Robert Maki
      The Oncologist 2001 6 4
    • Marine Ligands of the Pregnane X Receptor (PXR): An Overview
      Alejandro Carazo, Přemysl Mladěnka, Petr Pávek
      Marine Drugs 2019 17 10
    • Medicinal Chemistry of Anticancer Drugs
      Carmen Avendaño, J. Carlos Menéndez
      2015
    • Medicinal Chemistry of Anticancer Drugs
      Carmen Avendaño, J. Carlos Menéndez
      2008
    • Piperazine ring formation by a single-module NRPS and cleavage by an α-KG-dependent nonheme iron dioxygenase in brasiliamide biosynthesis
      Bochuan Yuan, Dong Liu, Xin Guan, Yunchen Yan, Jianping Zhang, Yiping Zhang, Donghui Yang, Ming Ma, Wenhan Lin
      Applied Microbiology and Biotechnology 2020 104 14
    • Purification and Characterization of Bioactive Compounds fromStyela clava
      Bao Ju, Bin Chen, Xingrong Zhang, Chunling Han, Aili Jiang
      Journal of Chemistry 2014 2014
    • Resistance to Targeted ABC Transporters in Cancer
      Atish Patel, De-Shen Wang, Hong-May Sim, Suresh V. Ambudkar, Zhe-Sheng Chen
      2015 4
    • Yago Nieto
      2003 21
    • Anticancer Agents from Natural Products
      Rubén Henríquez, Glynn Faircloth, Carmen Cuevas
      2005
    • Basic Science of Cancer
      Kathleen W. Scotto, Tan A. Ince
      2000
    • Ecteinascidin-743
      Jeanne Held-Warmkessel
      Clinical Journal of Oncology Nursing 2003 7 3
    • Methods of Cancer Diagnosis, Therapy, and Prognosis
      Ernesto Yagüe, Selina Raguz
      2010
    • Encyclopedia of Marine Biotechnology
      Samiha Tabassum Ghori, Vishaalini Kamali Raja, Uthira Muralitharan, Aathira Maikkara, Ayyavu Mahesh
      2020
    • Handbook of Anticancer Drugs from Marine Origin
      Harika Atmaca, Emir Bozkurt
      2015
    • Handbook of Molecular Microbial Ecology II
      Walter C. Dunlap, Paul F. Long, Marcel Jaspars
      2011
    • Investigating Seafloors and Oceans
      Antony Joseph
      2017
    • Mechanisms of Resistance to Conventional Therapies for Osteosarcoma
      Louise Marchandet, Morgane Lallier, Céline Charrier, Marc Baud’huin, Benjamin Ory, François Lamoureux
      Cancers 2021 13 4
    • Regional Cancer Therapy
      Ulrike S. Stein, Wolfgang Walther, Peter M. Schlag
      2007
    • Underwater treasures for cancer treatment
      Janet Fricker
      Drug Discovery Today 2001 6 12

    Article usage

    Article usage: June 2000 to April 2021

    AbstractFullPdf
    Jun 2000130116179
    Jul 2000255654
    Aug 2000114658
    Sep 200074352
    Oct 200074546
    Nov 200074739
    Dec 200033332
    Total 2000190386460
    Jan 2001133536
    Feb 2001123940
    Mar 2001113132
    Apr 2001113132
    May 200113047
    Jun 200122029
    Jul 200122330
    Aug 200122129
    Sep 200172828
    Oct 200172946
    Nov 200143042
    Dec 200121725
    Total 200174334416
    Jan 200242937
    Feb 200222320
    Mar 200222334
    Apr 200232433
    May 200252017
    Jun 2002122624
    Jul 200281312
    Aug 200201811
    Sep 200261815
    Oct 200221421
    Nov 200201624
    Dec 200231122
    Total 200247235270
    Jan 200391821
    Feb 20031810
    Mar 200311310
    Apr 200321418
    May 200321515
    Jun 200371416
    Jul 2003121912
    Aug 2003172038
    Sep 2003162325
    Oct 2003162922
    Nov 2003262233
    Dec 2003222825
    Total 2003131223245
    Jan 2004172225
    Feb 2004122922
    Mar 2004122640
    Apr 2004111735
    May 2004181722
    Jun 2004162613
    Jul 200420195
    Aug 2004201711
    Sep 2004272317
    Oct 2004191918
    Nov 2004294736
    Dec 200424169
    Total 2004225278253
    Jan 2005222618
    Feb 200591311
    Mar 200561736
    Apr 200561521
    May 200591519
    Jun 2005101011
    Jul 2005773
    Aug 200551318
    Sep 2005231318
    Oct 200520146
    Nov 2005152321
    Dec 2005161418
    Total 2005148180200
    Jan 2006161916
    Feb 2006262619
    Mar 200691415
    Apr 2006202111
    May 200615117
    Jun 2006121715
    Jul 20061668
    Aug 20061069
    Sep 200613158
    Oct 2006211616
    Nov 2006171615
    Dec 200625216
    Total 2006200188145
    Jan 2007142415
    Feb 2007181517
    Mar 2007142112
    Apr 2007102312
    May 2007479
    Jun 2007349
    Jul 2007766
    Aug 200710132
    Sep 2007357
    Oct 2007111412
    Nov 20071276
    Dec 20074167
    Total 2007110155114
    Jan 20081578
    Feb 200891410
    Mar 2008101914
    Apr 2008151814
    May 20081687
    Jun 200817311
    Jul 20082876
    Aug 20081962
    Sep 20081717
    Oct 20081647
    Nov 20082285
    Dec 2008844
    Total 20081929995
    Jan 200929620
    Feb 200926910
    Mar 20091595
    Apr 2009301013
    May 200914126
    Jun 20091265
    Jul 20091585
    Aug 20091286
    Sep 20092043
    Oct 2009221212
    Nov 20091837
    Dec 20091588
    Total 200922895100
    Jan 20101145
    Feb 2010201216
    Mar 201012138
    Apr 201014118
    May 20101476
    Jun 20101013
    Jul 201011104
    Aug 20101035
    Sep 20101054
    Oct 201012911
    Nov 2010201511
    Dec 2010964
    Total 20101539685
    Jan 20118104
    Feb 2011366
    Mar 20111499
    Apr 2011779
    May 20111136
    Jun 20118177
    Jul 201166611
    Aug 20116859
    Sep 20119985
    Oct 20118464
    Nov 20118963
    Dec 201115346
    Total 20116108779
    Jan 20129414
    Feb 20126472
    Mar 20129937
    Apr 2012901212
    May 20129244
    Jun 20125434
    Jul 201275310
    Aug 20129726
    Sep 20123205
    Oct 20124455
    Nov 20126815
    Dec 201280412
    Total 20128894576
    Jan 201310366
    Feb 20137356
    Mar 201385310
    Apr 201385115
    May 20139465
    Jun 201399322
    Jul 201383101
    Aug 20139858
    Sep 20135846
    Oct 20137075
    Nov 20134866
    Dec 20134877
    Total 201394410267
    Jan 201462416
    Feb 201441157
    Mar 201465312
    Apr 201483304
    May 20143439
    Jun 201454113
    Jul 20149444
    Aug 201482102
    Sep 201477116
    Oct 201460148
    Nov 201449108
    Dec 20146324
    Total 201476410793
    Jan 20155751
    Feb 20154053
    Mar 20156037
    Apr 20155423
    May 20154735
    Jun 20153959
    Jul 201539189
    Aug 201534106
    Sep 20159252
    Oct 2015501311
    Nov 2015292010
    Dec 201543537
    Total 201558414273
    Jan 2016461067
    Feb 2016311145
    Mar 20162611510
    Apr 20164643
    May 20163643
    Jun 20163556
    Jul 201625106
    Aug 201636265
    Sep 20165097
    Oct 20162943
    Nov 201639151
    Dec 20164474
    Total 201644341960
    Jan 20173759
    Feb 20174135
    Mar 20174486
    Apr 20171853
    May 20172531
    Jun 20173935
    Jul 201763712
    Aug 20173021
    Sep 20172466
    Oct 20173277
    Nov 20171576
    Dec 20173052
    Total 20173986163
    Jan 20181510
    Feb 2018895
    Mar 201815144
    Apr 201811134
    May 201823276
    Jun 201818223
    Jul 201811121
    Aug 201819195
    Sep 201816173
    Oct 20183173
    Nov 20184286
    Dec 20182328
    Total 201814521148
    Jan 20196123
    Feb 20192163
    Mar 20193114
    Apr 20190183
    May 20192153
    Jun 2019663
    Jul 2019084
    Aug 201911010
    Sep 20192414
    Oct 20197238
    Nov 20193117
    Dec 20190126
    Total 20193218358
    Jan 2020280
    Feb 2020342
    Mar 2020262
    Apr 2020083
    May 20200101
    Jun 2020274
    Jul 20200112
    Aug 2020163
    Sep 20201221
    Oct 20206168
    Nov 20202215
    Dec 20205212
    Total 20202414033
    Jan 20216157
    Feb 20211166
    Mar 20213172
    Apr 2021291
    Total 2021125716
    Total654338233049
    PreviousNext
    Back to top
    Article Alerts
    Email Article

    Thank you for your interest in spreading the word on PNAS.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation
    (Your Name) has sent you a message from PNAS
    (Your Name) thought you would like to see the PNAS web site.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Citation Tools
    Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation
    Shengkan Jin, Barbara Gorfajn, Glynn Faircloth, Kathleen W. Scotto
    Proceedings of the National Academy of Sciences Jun 2000, 97 (12) 6775-6779; DOI: 10.1073/pnas.97.12.6775

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    Request Permissions
    Share
    Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation
    Shengkan Jin, Barbara Gorfajn, Glynn Faircloth, Kathleen W. Scotto
    Proceedings of the National Academy of Sciences Jun 2000, 97 (12) 6775-6779; DOI: 10.1073/pnas.97.12.6775
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
    • Tweet Widget
    • Facebook Like
    • Mendeley logo Mendeley
    Proceedings of the National Academy of Sciences: 97 (12)
    Table of Contents

    Submit

    Sign up for Article Alerts

    Jump to section

    • Article
      • Abstract
      • Materials and Methods
      • Results
      • Discussion
      • Acknowledgments
      • Footnotes
      • Abbreviations
      • References
    • Figures & SI
    • Info & Metrics
    • PDF

    You May Also be Interested in

    Water from a faucet fills a glass.
    News Feature: How “forever chemicals” might impair the immune system
    Researchers are exploring whether these ubiquitous fluorinated molecules might worsen infections or hamper vaccine effectiveness.
    Image credit: Shutterstock/Dmitry Naumov.
    Reflection of clouds in the still waters of Mono Lake in California.
    Inner Workings: Making headway with the mysteries of life’s origins
    Recent experiments and simulations are starting to answer some fundamental questions about how life came to be.
    Image credit: Shutterstock/Radoslaw Lecyk.
    Cave in coastal Kenya with tree growing in the middle.
    Journal Club: Small, sharp blades mark shift from Middle to Later Stone Age in coastal Kenya
    Archaeologists have long tried to define the transition between the two time periods.
    Image credit: Ceri Shipton.
    Mouse fibroblast cells. Electron bifurcation reactions keep mammalian cells alive.
    Exploring electron bifurcation
    Jonathon Yuly, David Beratan, and Peng Zhang investigate how electron bifurcation reactions work.
    Listen
    Past PodcastsSubscribe
    Panda bear hanging in a tree
    How horse manure helps giant pandas tolerate cold
    A study finds that giant pandas roll in horse manure to increase their cold tolerance.
    Image credit: Fuwen Wei.

    Similar Articles

    Site Logo
    Powered by HighWire
    • Submit Manuscript
    • Twitter
    • Facebook
    • RSS Feeds
    • Email Alerts

    Articles

    • Current Issue
    • Special Feature Articles – Most Recent
    • List of Issues

    PNAS Portals

    • Anthropology
    • Chemistry
    • Classics
    • Front Matter
    • Physics
    • Sustainability Science
    • Teaching Resources

    Information

    • Authors
    • Editorial Board
    • Reviewers
    • Subscribers
    • Librarians
    • Press
    • Cozzarelli Prize
    • Site Map
    • PNAS Updates
    • FAQs
    • Accessibility Statement
    • Rights & Permissions
    • About
    • Contact

    Feedback    Privacy/Legal

    Copyright © 2021 National Academy of Sciences. Online ISSN 1091-6490